The primary objective of the Phase 2 study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.
The secondary objectives of the study are:
To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo
To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
To assess the concentrations of REGN10933 and REGN10987 in serum over time
To assess the immunogenicity of REGN10933 and REGN10987